Epilepsy Trial, Recruiting NCT05673915 Sponsor: Mayo Clinic Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT05673915
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a type of epilepsy that affects the whole brain, a specific part of the brain, or a sleep-related form of epilepsy involving brain activity disruptions.
  • You have at least 2 seizures per month that can be counted and tracked, or your brain activity shows a certain pattern of abnormal electrical activity at least 50% of the time (confirm with trial site).
  • At least 2 different seizure medications have been tried but have not successfully controlled your seizures.
  • You are able to stay on the same seizure medication throughout the whole study (emergency or rescue medications are still allowed).
  • You, or a person legally authorized to make decisions for you, can understand the consent forms and keep a daily seizure diary written in English.

Who may not be able to join:

  • You have another illness that is likely to get worse over the course of the study.
  • Your episodes have been identified as psychological rather than caused by epileptic brain activity (sometimes called "non-epileptic seizures").
  • You have had a suicide attempt or been admitted to a psychiatric facility in the past 2 years.
  • You have a skin condition on your scalp that would interfere with wearing electrode sensors, or you have an allergy to silver.
  • You are pregnant, or if there is a chance you could be pregnant, a blood pregnancy test will be required before joining.
  • You have an implanted medical device such as a pacemaker (a vagus nerve stimulator, or VNS, is an exception and is allowed).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Brian Lundstrom, MD, PhD, Mayo Clinic

Phone: 507-538-6606

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
12 April 2023
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Seizure Count

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov